Company intelligence / Profile preview
PhotonPharma
Fort Collins, Colorado, United Statesphotonpharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
PhotonPharma’s lead program Innocell™ has received FDA clearance for a Phase 1 clinical study in patients with recurrent epithelial ovarian cancer. The trial will assess safety and immunogenicity. Preclinical studies have demonstrated efficacy and safety in animal models. No human efficacy data yet available as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Autologous cell therapycancer vaccine (autologous tumor cell-based immunotherapy)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with Colorado State University for preclinical researchCity of Hope mentioned as a collaborator during CEO transition announcement
Beyond the preview
Go deeper on PhotonPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PhotonPharma.